Randomised phase II study of cisplatin and 5-fluoroura advanced squamous cell oesophageal cancer

European Journal of Cancer

33, 1216-1220

DOI: 10.1016/s0959-8049(97)00088-9

Citation Report

#	Article	IF	Citations
1	Chemotherapy and Radiotherapy in Esophageal Cancer. , 0, , 122-133.		0
2	Correspondence. European Journal of Cancer, 1998, 34, 1983.	1.3	9
3	Correspondence. European Journal of Cancer, 1998, 34, 1982-1983.	1.3	9
4	Outpatient 5-Fluorouracil, Folinic Acid and Cisplatin in Patients with Advanced Esophageal Carcinoma. Acta OncolÃ³gica, 1999, 38, 255-259.	0.8	19
5	Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect. Surgery Today, 1999, 29, 689-694.	0.7	6
6	Chemotherapy of Esophageal Carcinoma. Oncology Research and Treatment, 1999, 22, 98-104.	0.8	5
7	A Case of Inoperable Esophageal Carcinoma with Hepatic and Nodal Metastases Which Showed a Long-term Survival after Chemoradiotherapy Including Nedaplatin. Japanese Journal of Clinical Oncology, 2000, 30, 406-409.	0.6	8
9	Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus. European Journal of Cancer, 2001, 37, 470-477.	1.3	46
10	A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. European Journal of Cancer, 2001, 37, 1828-1832.	1.3	16
11	Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anti-Cancer Drugs, 2001, 12, 513-517.	0.7	34
12	What Is the â€œBestâ€•Platinum: Cisplatin, Carboplatin, or Oxaliplatin?. Cancer Investigation, 2001, 19, 756-760.	0.6	46
13	Questionable Benefit of Melatonin for Antioxidant Pharmacologic Therapy. Journal of Clinical Oncology, 2002, 20, 4127-4129.	0.8	11
14	Radiation Recall Dermatitis May Represent the Koebner Phenomenon. Journal of Clinical Oncology, 2002, 20, 4130-4130.	0.8	22
15	HER2 in Brain Metastases: Issues of Concordance, Survival, and Treatment. Journal of Clinical Oncology, 2002, 20, 4130-4133.	0.8	54
16	Do Quality-of-Life Randomized Clinical Trials Support Clinicians in Their Decision-Making?. Journal of Clinical Oncology, 2002, 20, 4126-4127.	0.8	17
17	Cardiac Dysfunction in Clinical Trials of Trastuzumab. Journal of Clinical Oncology, 2002, 20, 4119-4120.	0.8	5
18	Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Annals of Oncology, 2002, 13, 721-729.	0.6	67
19	Epirubicin, Cisplatin, and Protracted Venous-Infusion Fluorouracil in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 2002, 20, 4124-4126.	0.8	3

#	Article	IF	Citations
20	Use and Abuse of Statistics in Evidence-Based Medicine. Journal of Clinical Oncology, 2002, 20, 4122-4124.	0.8	3
21	Need for a Quantitative Meta-Analysis of Trials of Adjuvant Interferon in Melanoma. Journal of Clinical Oncology, 2002, 20, 4120-4122.	0.8	7
22	Prostate Cancer Risk Groups and Comparisons: Fruitless or Fruitful?. Journal of Clinical Oncology, 2002, 20, 4129-4130.	0.8	7
23	Retrospective Assessment of Hypercoagulability in Breast Cancer Prevention Trial. Journal of Clinical Oncology, 2002, 20, 4133-4134.	0.8	9
24	Phase I Study of Combination Chemotherapy With 5-Fluorouracil (5-FU) and Nedaplatin (NDP). American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 565-569.	0.6	20
25	A Pilot Trial of Combination Cisplatin, 5-Fluorouracil and Interferon-Î± in the Treatment of Advanced Esophageal Carcinoma. Chemotherapy, 2002, 48, 211-216.	0.8	18
26	Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. European Journal of Cancer, 2002, 38, 661-666.	1.3	12
27	Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. European Journal of Cancer, 2002, 38, 1495-1500.	1.3	17
28	New developments in the treatment of esophageal cancer. Current Oncology Reports, 2002, 4, 213-221.	1.8	15
29	Activity of vinorelbine in gastrointestinal cancers. Critical Reviews in Oncology/Hematology, 2002, 42, 173-178.	2.0	10
30	Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. British Journal of Cancer, 2002, 86, 669-673.	2.9	73
31	A Phase II Trial of Docetaxel and CPT-11 in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia. International Journal of Gastrointestinal Cancer, 2003, 32, 115-124.	0.4	34
32	Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. British Journal of Cancer, 2003, 89, 2045-2050.	2.9	93
33	Esophageal Cancer. New England Journal of Medicine, 2003, 349, 2241-2252.	13.9	2,582
34	Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality. European Journal of Surgical Oncology, 2003, 29, 884-889.	0.5	8
35	Oesophageal cancer: new developments in systemic therapy. Cancer Treatment Reviews, 2003, 29, 525-532.	3.4	59
36	Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. European Journal of Cancer, 2003, 39, 1384-1394.	1.3	336
37	Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. British Journal of Cancer, 2003, 89, 630-633.	2.9	71

#	Article	IF	Citations
38	Colon Cancer and Other Gastrointestinal Malignancies. , 2003, , 417-440.		1
39	Suppressive effect of CPT-11 on rat esophageal tumorigenesis induced by N-nitrosomethylbenzylamine. Oncology Reports, 2004, 12, 1169.	1.2	1
40	A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer. Clinical Cancer Research, 2004, 10, 1928-1934.	3.2	32
41	Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Annals of Oncology, 2004, 15, 230-235.	0.6	30
42	Innovative Drugs and Strategies in the Treatment of Upper Gastrointestinal Tract Carcinomas. Oncology Research and Treatment, 2004, 27, 47-53.	0.8	0
43	A phase II study of carboplatin and paclitaxel in esophageal cancer. Annals of Oncology, 2004, 15, 960-965.	0.6	46
44	Esophageal cancer: chemotherapy as palliative therapy. Annals of Oncology, 2004, 15, iv97-iv100.	0.6	11
45	A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Annals of Oncology, 2004, 15, 955-959.	0.6	212
46	Treatment of metastatic esophagus and gastric cancer. Seminars in Oncology, 2004, 31, 574-587.	0.8	43
47	Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study. Investigational New Drugs, 2004, 22, 91-97.	1.2	30
49	Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. British Journal of Cancer, 2005, 92, 2129-2133.	2.9	57
51	Palliative therapy. Journal of Surgical Oncology, 2005, 92, 246-256.	0.8	50
53	Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer. Journal of Korean Medical Science, 2005, 20, 618.	1.1	13
54	Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601.	1.9	128
55	Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Annals of Oncology, 2005, 16, 1320-1325.	0.6	55
56	Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. British Journal of Cancer, 2005, 93, 1112-1116.	2.9	22
57	Docetaxel and Cisplatin as First-Line Treatment for Patients with Metastatic Esophageal Cancer: A Pilot Study. Oncology Research and Treatment, 2005, 28, 647-650.	0.8	16
58	A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma. Oncology, 2005, 69, 130-134.	0.9	12

#	Article	IF	Citations
59	Systemic treatment for oesophageal cancer. European Journal of Cancer, 2005, 41, 664-672.	1.3	31
60	Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opinion on Investigational Drugs, 2006, 15, 131-153.	1.9	7
61	Palliative treatments for patients with inoperable gastroesophageal cancers. International Journal of Palliative Nursing, 2006, 12, 306-317.	0.2	3
64	Phase II Trial of Gemcitabine Plus Irinotecan In Patients With Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 116-122.	0.6	15
65	Incurable Esophageal Cancer: Patterns of Tumor Spread and Therapeutic Consequences. World Journal of Surgery, 2006, 30, 183-190.	0.8	17
66	New developments in palliative therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 959-978.	1.0	40
67	Esophagus cancer. Gastroenterologie Clinique Et Biologique, 2006, 30, 5-15.	0.9	3
68	Endoscopic Oncology. , 2006, , .		0
69	Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. , 2006, , CD004063.		40
70	First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. British Journal of Cancer, 2007, 96, 1348-1352.	2.9	41
71	Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 829-835.	0.6	12
72	Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience. Chemotherapy, 2007, 53, 449-453.	0.8	27
73	Second-line therapy for esophageal cancer. Expert Review of Anticancer Therapy, 2007, 7, 871-876.	1.1	1
74	Pharmacotherapy for Oesophagogastric Cancer. Drugs, 2007, 67, 2539-2556.	4.9	4
75	Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. British Journal of Cancer, 2007, 96, 432-438.	2.9	35
76	A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naÃ¯ve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemotherapy and Pharmacology, 2007, 61, 83-88.	1.1	13
77	State of the art and future perspectives in cytostatic treatment of esophageal cancer. European Surgery - Acta Chirurgica Austriaca, 2007, 39, 151-157.	0.3	3
78	Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Medical Oncology, 2007, 24, 407-412.	1.2	33

#	Article	IF	Citations
79	High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiation Medicine, 2007, 25, 373-377.	0.8	18
80	Multimodal treatment of oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 947-963.	1.0	17
81	A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 77-84.	1.1	38
82	Interactions of anticancer drugs with usual and mismatch base pairs â€" Density functional theory studies. Biophysical Chemistry, 2008, 136, 50-58.	1.5	26
83	Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. British Journal of Cancer, 2008, 99, 1395-1401.	2.9	14
84	Comparison of an inflammationâ€based prognostic score (GPS) with performance status (ECOGâ€ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e325-9.	1.4	50
85	Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Ecological Management and Restoration, 2008, 21, 496-501.	0.2	16
86	Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Ecological Management and Restoration, 2008, 21, 607-611.	0.2	14
87	Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Ecological Management and Restoration, 2008, 21, 697-703.	0.2	41
88	Esophageal cancer: current and emerging therapy modalities. Expert Review of Anticancer Therapy, 2008, 8, 1433-1448.	1.1	42
89	A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 29-33.	0.6	49
90	Management of Esophageal Carcinoma Associated with Cirrhosis: A Retrospective Case-Control Analysis. Journal of Oncology, 2009, 2009, 1-5.	0.6	13
91	Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. Journal of Oncology, 2009, 2009, 1-8.	0.6	36
92	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	0.6	2
93	Cetuximab plus cisplatinâ€"5-fluorouracil versus cisplatinâ€"5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology, 2009, 20, 1667-1673.	0.6	206
94	Phase II trial of docetaxelâ€"irinotecan combination in advanced esophageal cancer. Annals of Oncology, 2009, 20, 1242-1248.	0.6	33
95	A Phase II Study of Paclitaxel and Nedaplatin as First-line Chemotherapy in Patients with Advanced Esophageal Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 582-587.	0.6	26
96	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Investigational New Drugs, 2009, 27, 366-373.	1.2	4

#	Article	IF	Citations
97	Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1111-1119.	1.1	22
98	Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 327-333.	1.1	28
99	Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Advanced Drug Delivery Reviews, 2009, 61, 388-401.	6.6	30
100	Emerging drugs for esophageal cancer. Expert Opinion on Emerging Drugs, 2009, 14, 329-339.	1.0	17
101	Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anti-Cancer Drugs, 2009, 20, 165-173.	0.7	12
102	Second-Line Combination Chemotherapy with Docetaxel and Nedaplatin for Cisplatin-Pretreated Refractory Metastatic/Recurrent Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2009, 4, 1017-1021.	0.5	41
103	Current Gene Expression Studies in Esophageal Carcinoma. Current Genomics, 2009, 10, 534-539.	0.7	25
104	Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-Fluorouracil/Cisplatin Pretreated Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 624-628.	0.6	38
105	Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. British Journal of Cancer, 2010, 103, 845-851.	2.9	19
106	A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 31-36.	1.1	26
107	Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology, 2010, 66, 1159-1165.	1.1	33
109	Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer, 2010, 10, 510.	1.1	36
110	Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Ecological Management and Restoration, 2010, 23, 646-651.	0.2	48
111	Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Ecological Management and Restoration, 2010, 23, 641-645.	0.2	38
112	Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. The Cochrane Library, 2010, , CD004063.	1.5	4
113	Palliative Chemotherapy Does Not Improve Survival in Metastatic Esophageal Cancer. Oncology, 2010, 79, 46-54.	0.9	20
114	Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy. Oncology, 2010, 79, 363-369.	0.9	1
115	Hsp90 as a therapeutic target in patients with oesophageal carcinoma. Expert Opinion on Therapeutic Targets, 2010, 14, 317-328.	1.5	13

#	Article	IF	Citations
116	The establishment of a new mouse model with orthotopic esophageal cancer showing the esophageal stricture. Cancer Letters, 2010, 293, 207-212.	3.2	21
117	Gastrointestinal Oncology. , 2011, , .		2
118	Second-line combination chemotherapy with docetaxel and nedaplatin for metastatic or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus cisplatin. Esophagus, 2011, 8, 179-185.	1.0	1
119	Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus. Oncology, 2011, 80, 307-313.	0.9	95
120	Efficacy of Concurrent Chemoradiotherapy as a Palliative Treatment in Stage IVB Esophageal Cancer Patients with Dysphagia. Japanese Journal of Clinical Oncology, 2011, 41, 964-972.	0.6	36
124	Elimination of esophageal multiple precancerous lesions by chemotherapy: potential chemoprevention of metachronous multiple cancer development after curative treatment. Esophagus, 2012, 9, 203-209.	1.0	2
127	A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. Cancer Chemotherapy and Pharmacology, 2013, 71, 905-911.	1.1	22
128	CÃ¡ncer de esÃ³fago. Medicine, 2013, 11, 1505-1511.	0.0	1
129	A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Medical Oncology, 2013, 30, 343.	1.2	50
130	Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer. Journal of Thoracic Oncology, 2013, 8, 673-684.	0.5	21
131	New and emerging combination therapies for esophageal cancer. Cancer Management and Research, 2013, 5, 133.	0.9	28
133	A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2014, 74, 1207-1215.	1.1	29
135	Targeted therapies in metastatic esophageal cancer: Advances over the past decade. Critical Reviews in Oncology/Hematology, 2014, 91, 186-196.	2.0	32
136	A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI). Esophagus, 2014, 11, 183-188.	1.0	28
137	Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma. Oncology Reports, 2014, 32, 1188-1192.	1.2	11
138	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. BMC Cancer, 2015, 15, 693.	1.1	23
139	A retrospective study of paclitaxel combining nedaplatin chemotherapy for esophageal cancer. Anti-Cancer Drugs, 2015, 26, 101-105.	0.7	7
140	Esophageal Cancer: Molecular Mechanisms, Diagnosis and Treatment. , 2015, , 201-228.		1

#	Article	IF	Citations
141	Clinical Significance of Surgical Resection for the Recurrence of Esophageal Cancer After Radical Esophagectomy. Annals of Surgical Oncology, 2015, 22, 240-246.	0.7	36
142	A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). Japanese Journal of Clinical Oncology, 2015, 45, 494-498.	0.6	24
143	miR-634 Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity. Cancer Research, 2015, 75, 3890-3901.	0.4	50
144	Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. Medical Oncology, 2015, 32, 127.	1.2	16
145	Salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients: A retrospective analysis. Brachytherapy, 2015, 14, 531-536.	0.2	13
148	Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 24744-24751.	0.8	25
149	Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 228-235.	0.6	24
150	Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. Ecological Management and Restoration, 2016, 30, n/a-n/a.	0.2	9
152	Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: AÂSingle-Arm, Multicenter Phase 2 Study. Journal of Thoracic Oncology, 2016, 11, 910-917.	0.5	51
153	Cervical esophageal cancer: a gap in cancer knowledge. Annals of Oncology, 2016, 27, 1664-1674.	0.6	75
154	A phase IIa study of rhLTÎ±-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma. Medical Oncology, 2016, 33, 125.	1.2	3
155	Cancer of the Esophagus. , 2016, , 843-864.e7.		0
156	Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving firstâ€line chemotherapy. Cancer Medicine, 2016, 5, 778-786.	1.3	30
157	Irinotecan plus fluorouracilâ€based regimen as second or thirdâ€line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma. Thoracic Cancer, 2016, 7, 246-250.	0.8	13
158	Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Cancer Science, 2016, 107, 486-490.	1.7	44
159	Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Science, 2016, 107, 764-772.	1.7	19
160	Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. Ecological Management and Restoration, 2016, 30, 1-7.	0.2	14
161	The Development of Systemic Therapies for Esophageal and Gastric Cancers. , 2016, , 153-170.		0

#	Article	IF	Citations
162	First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. Oncology, 2016, 90, 88-96.	0.9	3
163	Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 1143-1152.	1.1	30
164	Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncology Letters, 2017, 13, 704-714.	0.8	8
165	Issues in the Management of Esophagogastric Cancer in Geriatric Patients. Surgical Oncology Clinics of North America, 2017, 26, 335-346.	0.6	1
166	Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer. European Journal of Cancer, 2017, 78, 28-36.	1.3	24
167	Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. The Cochrane Library, 2017, 2017, CD004063.	1.5	60
168	Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model. Annals of Nutrition and Metabolism, 2017, 71, 247-252.	1.0	6
169	Efficacy and safety of recombinant human lymphotoxinâ€Ì± derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, openâ€label, controlled, phase 2b trial. Cancer, 2017, 123, 3986-3994.	2.0	6
170	Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. Chemotherapy, 2017, 62, 215-224.	0.8	5
172	CÃ¡ncer de esÃ³fago. EMC - Tratado De Medicina, 2017, 21, 1-7.	0.0	0
173	Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Settingâ€”Practice and Outcomes. Frontiers in Oncology, 2017, 7, 151.	1.3	2
175	A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. International Journal of Clinical Oncology, 2018, 23, 466-472.	1.0	39
176	Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). The Lancet Gastroenterology and Hepatology, 2018, 3, 114-124.	3.7	64
177	Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma inÂvivo. Cancer Letters, 2018, 417, 1-10.	3.2	23
178	Proximal/Cervical Esophageal Cancer. Practical Guides in Radiation Oncology, 2018, , 3-19.	0.0	0
179	Clinical results of multimodality therapy for esophageal cancer with distant metastasis. Journal of Thoracic Disease, 2018, 10, 1500-1510.	0.6	4
180	Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiation Oncology, 2018, 13, 233.	1.2	15
181	Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population. Current Oncology Reports, 2018, 20, 99.	1.8	9

#	Article	IF	Citations
182	The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cell Biochemistry and Function, 2018, 36, 398-407.	1.4	16
183	Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report. OncoTargets and Therapy, 2018, Volume 11, 5821-5826.	1.0	7
184	Current therapeutic landscape for advanced gastroesophageal cancers. Annals of Translational Medicine, 2018, 6, 78-78.	0.7	7
185	Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus. Oncology, 2018, 95, 116-120.	0.9	2
186	DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system. Oncology Letters, 2018, 16, 1869-1875.	0.8	14
187	Recent advancements in esophageal cancer treatment in Japan. Annals of Gastroenterological Surgery, 2018, 2, 253-265.	1.2	35
188	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	2.0	34
189	Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. International Journal of Clinical Oncology, 2018, 23, 1076-1083.	1.0	7
190	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Annals of the New York Academy of Sciences, 2018, 1434, 342-359.	1.8	56
191	Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. Journal of Global Oncology, 2019, 5, 1-10.	0.5	4
192	S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. Anticancer Research, 2019, 39, 3931-3936.	0.5	5
193	Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma. In Vivo, 2019, 33, 2249-2254.	0.6	4
194	Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma. Oncology Research and Treatment, 2019, 42, 115-122.	0.8	7
195	Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). European Journal of Cancer, 2019, 111, 12-20.	1.3	15
196	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus, 2019, 16, 1-24.	1.0	394
197	Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus, 2019, 16, 25-43.	1.0	321
198	A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study. Annals of Surgical Oncology, 2019, 26, 321-328.	0.7	61
199	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. Expert Opinion on Pharmacotherapy, 2019, 20, 357-366.	0.9	9

#	Article	IF	Citations
200	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and Liver Disease, 2020, 52, 347-350.	0.4	2
201	Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the firstâ€line treatment of advanced esophageal squamous cell carcinoma. Cancer Communications, 2020, 40, 711-720.	3.7	68
202	Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, 707-715.	0.4	29
203	Olaparib Potentiates Anticancer Drug Cytotoxicity via 53BP1 in Oesophageal Squamous Cell Carcinoma Cells. Anticancer Research, 2020, 40, 813-823.	0.5	7
205	Esophageal brachytherapy: Institut Gustave Roussy's experience. Brachytherapy, 2020, 19, 499-509.	0.2	7
206	Long-Term Survival in an Esophageal Cancer Patient with Multiple Recurrences. Journal of Gastrointestinal Cancer, 2020, 51, 695-697.	0.6	1
207	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Annals of Oncology, 2020, 31, 228-235.	0.6	60
208	Treatment-related complications in patients with esophageal cancer: A systematic review and network meta-analysis. Journal of the Royal College of Surgeons of Edinburgh, 2021, 19, 37-48.	0.8	4
210	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399.	1.4	1
211	Palliative brachytherapy and external beam radiotherapy for dysphagia from esophageal cancer: a nationwide survey in Japan. Japanese Journal of Clinical Oncology, 2021, 51, 950-955.	0.6	3
212	<scp>SHRâ€1316</scp>, an <scp>antiâ€PDâ€L1</scp> antibody, plus chemotherapy as the firstâ€line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase <scp>2</scp> study. Thoracic Cancer, 2021, 12, 1373-1381.	0.8	15
214	Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 170-185.	1.8	1
216	Efficacy and safety of vinorelbine and cisplatin regimen of different doses and intensities for neoadjuvant chemotherapy in patients with locally advanced esophageal carcinoma. Annals of Translational Medicine, 2021, 9, 660-660.	0.7	2
217	Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5â€fluorouracil followed by stereotactic body radiotherapy: A case report. Molecular and Clinical Oncology, 2021, 15, 130.	0.4	1
218	The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy. Expert Opinion on Drug Safety, 2022, 21, 55-65.	1.0	11
220	Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. European Journal of Cancer, 2021, 154, 307-315.	1.3	4
222	Anesthesia for Esophageal Surgery. , 2011, , 415-443.		4
224	CHEMOTHERAPY AND RADIOTHERAPY AS PRIMARY TREATMENT OF ESOPHAGEAL CANCER. , 2008, , 509-526.		1

#	Article	IF	Citations
225	Recent advances in treating oesophageal cancer. F1000Research, 2020, 9, 1189.	0.8	50
226	Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget, 2017, 8, 80286-80294.	0.8	9
227	Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results. Oncotarget, 2019, 10, 847-855.	0.8	8
228	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 44971-44984.	0.8	13
229	Palliative Radiotherapy in the Local Management of Stage IVB Esophageal Cancer: Factors Affecting Swallowing and Survival. Anticancer Research, 2017, 37, 3085-3092.	0.5	12
230	Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy. Anticancer Research, 2017, 37, 6831-6837.	0.5	7
231	A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technology Assessment, 2005, 9, iii, 1-121.	1.3	77
232	Expression of thymidylate synthase and glutathione-s-transferase Ï€ in patients with esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2009, 15, 4316.	1.4	14
233	A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2013, 19, 5910.	1.4	18
234	A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2012, 4, 58-62.	0.6	25
235	The efficacy and toxicities of combined lobaplatin with paclitaxel as a first-line chemotherapy for advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2015, 7, 1749-55.	0.6	20
236	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	0.5	11
237	Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma. Cancer Research and Treatment, 2013, 45, 285-294.	1.3	12
238	Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. Cancer Research and Treatment, 2017, 49, 416-422.	1.3	27
239	A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Research and Treatment, 2017, 49, 816-823.	1.3	11
240	Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review. World Journal of Gastrointestinal Oncology, 2019, 11, 741-749.	0.8	25
241	Achalasia Combined with Esophageal Cancer Treated by Concurrent Chemoradiation Therapy. Gut and Liver, 2009, 3, 329-333.	1.4	3
242	Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology). , 2008, , 13-21.		0

#	Article	IF	Citations
243	Chemoradiation Therapy with Docetaxel/Fluorouracil/Nedaplatin for the Patients with Esophageal Cancer and Simultaneous Double Primary Malignancy. Nihon Ika Daigaku Igakkai Zasshi, 2008, 4, 197-200.	0.0	1
244	IVã€€æ¶ˆåŒ–å™¨ç™Œã®å†…ç§‘çš„æ²»ç™‚æ³•æ²»ç™‚æˆ¦ç•¥. Okayama Igakkai Zasshi, 2008, 119, 301-309.	0.0	0
245	Radiotherapy and Chemotherapy of Squamous Cell Carcinomas of the Hypopharynx and Esophagus. , 2010, , 1441-1447.		0
247	Cancer of the Esophagus. , 2012, , 839-858.		0
248	Chemoradiation Therapy with Docetaxel/Nedaplatin and Fluorouracil for Patients Older than 80 Years with Advanced Esophageal Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2012, 8, 143-146.	0.0	0
249	Benign and Malignant Tumors of the Esophagus. , 2013, , 579-598.		0
250	A Successfully Treated Case of Cervico-thoracic Esophageal Cancer by Larynx-preserving Esophagectomy in Team Medication. Nihon Ika Daigaku Igakkai Zasshi, 2013, 9, 20-24.	0.0	0
251	Ã–sophaguskarzinom und Karzinom des gastroÃ¶sophagealen Ãœberganges. , 2013, , 593-618.		0
253	Cancer of the Esophagus. , 2014, , 1207-1239.e7.		0
254	Ã–sophaguskarzinom. , 1998, , 590-605.		0
255	Chemotherapy and Chemoradiotherapy. , 2015, , 197-225.		1
257	Multimodality Management of Esophageal Malignancies beyond Endoscopy. , 2015, , 199-240.		0
259	Systemic Treatment of Esophageal Cancer. , 2016, , 325-344.		0
260	Ã–sophaguskarzinom beim alten und geriatrischen Patienten. , 2017, , 1-12.		0
261	Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma. Oncology & Hematology Review, 2018, 14, 82.	0.2	1
262	Ã–sophaguskarzinom beim alten und geriatrischen Patienten. , 2018, , 313-324.		0
264	Cancro dellâ€™esofago cervicale. EMC - Otorinolaringoiatria, 2018, 17, 1-17.	0.0	0
265	Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers. Cancer Research Statistics and Treatment, 2019, 2, 172.	0.1	0

#	Article	IF	Citations
266	Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: A systematic review. World Journal of Gastrointestinal Oncology, 2019, 11, 741-749.	0.8	2
267	Systemic Therapy for Esophageal Squamous Cell Carcinoma. Methods in Molecular Biology, 2020, 2129, 321-333.	0.4	1
268	Chemotherapy and Chemoradiotherapy. , 2020, , 253-282.		0
272	Ã–sophaguskarzinom. , 0, , 660-678.		0
274	Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview. Cancer Biology and Medicine, 2014, 11, 78-85.	1.4	10
275	Esophageal cancer chemotherapy: recent advances. Gastrointestinal Cancer Research: GCR, 2008, 2, 85-92.	0.8	58
276	Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointestinal Cancer Research: GCR, 2009, 3, 153-61.	0.8	44
277	Saudi Oncology Society clinical management guideline series. Esophageal cancer 2014. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1545-9.	0.5	0
278	State of the art management of metastatic gastroesophageal cancer. Annals of Translational Medicine, 2015, 3, 236.	0.7	4
279	Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. American Journal of Cancer Research, 2016, 6, 2345-2350.	1.4	17
281	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022, 386, 449-462.	13.9	419
283	Nivolumab in Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022, 386, 1958-1961.	13.9	1
284	Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment. Current Oncology, 2022, 29, 4868-4878.	0.9	0
285	Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	13
286	Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 992-1004.	0.6	145
287	Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study. Frontiers in Oncology, 0, 12, .	1.3	2
289	Survival in esophageal cancer patients with hematogenous distant organ metastases. Turkish Journal of Medical Sciences, 0, , .	0.4	8
291	Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1

#	Article	IF	Citations
292	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211383.	1.4	3
293	The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. Esophagus, 2023, 20, 524-532.	1.0	5
294	Gallbladder Cancer: Current Treatment Options and Therapeutics. , 2023, , 3-30.		0
295	First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nature Medicine, 2023, 29, 473-482.	15.2	39
296	Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma. Frontiers in Immunology, 0, 14, .	2.2	0
297	Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus, 2023, 20, 343-372.	1.0	36
298	An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Cancer Cell, 2023, 41, 919-932.e5.	7.7	6
302	Palliative Chemotherapy: CTx Regimen (First-Line, Second-Line, Targeted Therapies, and Immunotherapy). , 2023, , 129-138.		0
313	Neoplastic obstructions. , 2024, , 155-181.		0